CoreValve
CoreValve was acquired by Medtronic in 2009 for $700 million, plus milestone payments. CoreValve developed a Percutaneous Aortic Valve to replace open heart surgery with a minimally invasive approach. The product was approved in Europe and many other countries, with more than 25,000 patients treated to date. CoreValve is considered as one of the most successful private medtech exits in the last 10 years. The company was founded by Prof Jacques Seguin, a cardiac surgeon and repeat entrepreneur in the cardiovascular space.
Sector
Medical Devices
Strategies
Capital
Status
Exit
Website
CoreValve page on Medtronic.com
Related Articles
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.